These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
76 related articles for article (PubMed ID: 2399491)
1. Investigation of behavioral and electrophysiological responses induced by selective stimulation of CCKB receptors by using a new highly potent CCK analog, BC 264. Dauge V; Bohme GA; Crawley JN; Durieux C; Stutzmann JM; Feger J; Blanchard JC; Roques BP Synapse; 1990; 6(1):73-80. PubMed ID: 2399491 [TBL] [Abstract][Full Text] [Related]
2. [Study of induced effects by selective CCKB agonists cholecystokinin in the nociception and behavior in rodents]. Dauge V; Derrien M; Durieux C; Noble F; Corringer PJ; Roques BP Therapie; 1992 Nov; 47(6):531-9. PubMed ID: 1301645 [TBL] [Abstract][Full Text] [Related]
3. [3H]pBC 264, a suitable probe for studying cholecystokinin-B receptors: binding characteristics in rodent brains and comparison with [3H]SNF 8702. Durieux C; Ruiz-Gayo M; Corringer PJ; Bergeron F; Ducos B; Roques BP Mol Pharmacol; 1992 Jun; 41(6):1089-95. PubMed ID: 1614411 [TBL] [Abstract][Full Text] [Related]
4. Characterization of SNF 9007, a novel cholecystokinin/opoid ligand in mouse ileum in vitro: evidence for involvement of cholecystokininA and cholecystokininB receptors in regulation of ion transport. Rao RK; Levenson S; Fang SN; Hruby VJ; Yamamura HI; Porreca F J Pharmacol Exp Ther; 1994 Feb; 268(2):1003-9. PubMed ID: 8113956 [TBL] [Abstract][Full Text] [Related]
5. Antagonists of central and peripheral behavioral actions of cholecystokinin octapeptide. Crawley JN; Stivers JA; Hommer DW; Skirboll LR; Paul SM J Pharmacol Exp Ther; 1986 Feb; 236(2):320-30. PubMed ID: 3003339 [TBL] [Abstract][Full Text] [Related]
6. Distinct requirements for activation at CCK-A and CCK-B/gastrin receptors: studies with a C-terminal hydrazide analogue of cholecystokinin tetrapeptide (30-33). Lin CW; Holladay MW; Barrett RW; Wolfram CA; Miller TR; Witte D; Kerwin JF; Wagenaar F; Nadzan AM Mol Pharmacol; 1989 Dec; 36(6):881-6. PubMed ID: 2601685 [TBL] [Abstract][Full Text] [Related]
7. In vivo binding affinities of cholecystokinin agonists and antagonists determined using the selective CCKB agonist [3H]pBC 264. Durieux C; Ruiz-Gayo M; Roques BP Eur J Pharmacol; 1991 Dec; 209(3):185-93. PubMed ID: 1797561 [TBL] [Abstract][Full Text] [Related]
8. The selective CCK-B agonist, BC 264 injected in the antero-lateral part of the nucleus accumbens, reduces the spontaneous alternation behaviour of rats. Daugé V; Derrien M; Blanchard JC; Roques BP Neuropharmacology; 1992 Jan; 31(1):67-75. PubMed ID: 1542405 [TBL] [Abstract][Full Text] [Related]
9. Effects induced by BC 264, a selective agonist of CCK-B receptors, on morphine-dependent rats. Maldonado R; Valverde O; Derrien M; Tejedor-Real P; Roques BP Pharmacol Biochem Behav; 1994 Jun; 48(2):363-9. PubMed ID: 8090802 [TBL] [Abstract][Full Text] [Related]
10. Analysis of the behavioral activity of C- and N-terminal fragments of cholecystokinin octapeptide. Crawley JN; St-Pierre S; Gaudreau P J Pharmacol Exp Ther; 1984 Aug; 230(2):438-44. PubMed ID: 6086888 [TBL] [Abstract][Full Text] [Related]
11. Microinjection of cholecystokinin into the rat ventral tegmental area potentiates dopamine-induced hypolocomotion. Crawley JN Synapse; 1989; 3(4):346-55. PubMed ID: 2740993 [TBL] [Abstract][Full Text] [Related]
12. CholecystokininA and cholecystokininB receptors in neurons of the brainstem solitary complex of the rat: pharmacological identification. Branchereau P; Böhme GA; Champagnat J; Morin-Surun MP; Durieux C; Blanchard JC; Roques BP; Denavit-Saubié M J Pharmacol Exp Ther; 1992 Mar; 260(3):1433-40. PubMed ID: 1545402 [TBL] [Abstract][Full Text] [Related]
13. The CCKB receptor antagonist, L-365,260, elicits antidepressant-type effects in the forced-swim test in mice. Hernando F; Fuentes JA; Roques BP; Ruiz-Gayo M Eur J Pharmacol; 1994 Aug; 261(3):257-63. PubMed ID: 7813546 [TBL] [Abstract][Full Text] [Related]
14. CCKB receptors mediate CCK-8S-induced activation of dorsal hippocampus CA3 pyramidal neurons: an in vivo electrophysiological study in the rat. Gronier B; Debonnel G Synapse; 1995 Oct; 21(2):158-68. PubMed ID: 8584977 [TBL] [Abstract][Full Text] [Related]
15. Synthesis and biological activity of novel, potent and long-acting analogs of AC-CCK-7 with high affinity for peripheral (type A) receptors. Danho W; Makofske RC; Swistok J; Michalewsky J; Gabriel T; Marks N; Berg MJ; Baird L; Geiler V; Mackie G Pept Res; 1991; 4(2):59-65. PubMed ID: 1815779 [TBL] [Abstract][Full Text] [Related]
16. CCK8 effects on motivational and emotional states of rats involve CCKA receptors of the postero-median part of the nucleus accumbens. Daugé V; Steimes P; Derrien M; Beau N; Roques BP; Féger J Pharmacol Biochem Behav; 1989 Sep; 34(1):157-63. PubMed ID: 2626446 [TBL] [Abstract][Full Text] [Related]
17. Role of cholecystokinin-A and cholecystokinin-B receptors in anxiety. Hernandez-Gómez AM; Aguilar-Roblero R; Pérez de la Mora M Amino Acids; 2002; 23(1-3):283-90. PubMed ID: 12373548 [TBL] [Abstract][Full Text] [Related]
18. Structure-based design of new constrained cyclic agonists of the cholecystokinin CCK-B receptor. Blommaert AG; Dhôtel H; Ducos B; Durieux C; Goudreau N; Bado A; Garbay C; Roques BP J Med Chem; 1997 Feb; 40(5):647-58. PubMed ID: 9057851 [TBL] [Abstract][Full Text] [Related]
19. Increased neuronal responsiveness to cholecystokinin and dopamine induced by lesioning mesolimbic dopaminergic neurons: an electrophysiological study in the rat. Debonnel G; de Montigny C Synapse; 1988; 2(5):537-45. PubMed ID: 2903570 [TBL] [Abstract][Full Text] [Related]
20. Subtype-selective cholecystokinin receptor antagonists block cholecystokinin modulation of dopamine-mediated behaviors in the rat mesolimbic pathway. Crawley JN J Neurosci; 1992 Sep; 12(9):3380-91. PubMed ID: 1527584 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]